Lyell Immunopharma (LYEL) EBITDA Yield: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.74-0.34 (-3.69%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Lyell Immunopharma, Inc. (LYEL)	$214.05M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.35M	6.96%	4.54%	3.13%	3.13%
Compugen Ltd. (CGEN)vs ›	$211.80M	N/A	17.11%	12.89%	12.89%
Prelude Therapeutics Incorporated (PRLD)vs ›	$211.51M	N/A	N/A	N/A	N/A
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$215.07M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$209.16M	N/A	N/A	N/A	N/A
Pro-Dex, Inc. (PDEX)vs ›	$209.24M	6.56%	7.98%	8.26%	7.82%
Entrada Therapeutics, Inc. (TRDA)vs ›	$208.37M	N/A	11.62%	10.33%	10.33%
Whitehawk Therapeutics Inc (WHWK)vs ›	$207.51M	N/A	N/A	N/A	N/A
Sionna Therapeutics, Inc. (SION)vs ›	$205.89M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Lyell Immunopharma, Inc. (LYEL)

$214.05M

N/A

Niagen Bioscience Inc (NAGE)vs ›

$214.35M

6.96%

4.54%

3.13%

Compugen Ltd. (CGEN)vs ›

$211.80M

N/A

17.11%

12.89%

Prelude Therapeutics Incorporated (PRLD)vs ›

$211.51M

N/A

Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›

$215.07M

N/A

Electra Therapeutics Inc. (ETRA)vs ›

$209.16M

N/A

Pro-Dex, Inc. (PDEX)vs ›

$209.24M

6.56%

7.98%

8.26%

7.82%

Entrada Therapeutics, Inc. (TRDA)vs ›

$208.37M

N/A

11.62%

10.33%

Whitehawk Therapeutics Inc (WHWK)vs ›

$207.51M

N/A

Sionna Therapeutics, Inc. (SION)vs ›

$205.89M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

LYEL EBITDA Yield Metrics

LYEL Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics